The current outbreak of Ebola virus disease in the Democratic Republic of Congo (DRC) and Uganda is driven by Bundibugyo ebolavirus (BDBV), a less common Ebola species that causes viral haemorrhagic fever. Multiple reports describe BDBV as more difficult to respond to because specific, ready treatments and vaccines are not available. Sources note that BDBV can have a high fatality rate, with one report citing up to about 40% in general terms.
Public health reporting indicates the outbreak in the DRC has involved hundreds of confirmed cases, with deaths reported; figures vary across outlets, including references to around the hundreds of confirmed cases and deaths, and in some summaries the outbreak’s toll being described as nearly 120 to more than 200 suspected or confirmed fatalities.
Several sources also point to ongoing research and development efforts for Bundibugyo-specific vaccines and therapies, while emphasizing that options are not close to routine clinical use. Commentators cited by at least one outlet say that responders must rely on standard infection-control and public health measures while candidate vaccines and treatments are identified and assessed.
